Progress in gammaglobulin therapy for immunodeficiency: From subcutaneous to intravenous infusions and back again

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1153-1164

  Wasserman, Richard L ^a  

^a DallasAllergyImmunology   (United States)

Author keywords

hyaluronidase; immunoglobulin G; Immunologic deficiency syndromes; subcutaneous infusion

Indexed keywords

EXCIPIENT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; ISOENZYME; RECOMBINANT HYALURONIDASE; HYALURONOGLUCOSAMINIDASE; RECOMBINANT PROTEIN;

ANTIBODY SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; ASEPTIC MENINGITIS; CHEST TIGHTNESS; CHILL; COMMON VARIABLE IMMUNODEFICIENCY; CONSCIOUSNESS DISORDER; COUGHING; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FACE EDEMA; FATIGUE; FEVER; HEADACHE; HEMOLYSIS; HUMAN; HYPEROSMOLARITY; HYPOTENSION; IMMUNE DEFICIENCY; INFECTION; INFECTION PREVENTION; INJECTION SITE DISCOMFORT; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; KIDNEY FAILURE; MALAISE; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; OSMOLALITY; PATIENT COMPLIANCE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINUS PAIN; SUBSTITUTION THERAPY; THROMBOEMBOLISM; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; VOMITING; X LINKED AGAMMAGLOBULINEMIA; EQUIPMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PASSIVE IMMUNIZATION; PATHOLOGY; PATIENT SATISFACTION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

CLINICAL TRIALS, PHASE III AS TOPIC; GAMMA-GLOBULINS; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, INTRAMUSCULAR; PATIENT SATISFACTION; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 84878219460     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9740-x     Document Type: Article

References (83)

1. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255-63.
2. APIIEG. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency.2nd edition 2009. http://www.apiieg. org/files/1/APIIEG%20Consensus%20Recommendations%20Edition%201%20June%202008. pdf. Accessed 10/24/2011.
3. Bruton O. Agammaglobulinemia. Pediatrics. 1952;9(6):722-8.
4. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - A prospective, multi-national study. J Clin Immunol. 2006;26(2):177-85.
5. Long AA, Denburg JA, Dent PB. Hypogammaglobulinemia: therapeutic rationale. CMAJ. 1987;137(9):793-7.
6. MRC-WP, 1967. Hypogammaglobulinaemia in the United Kingdon. Summary report of a Medical Research Council working-party. Lancet. 1969;1(7587):163-8.
7. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1-10.
8. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28:413-37.
9. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101(4):435-9.
10. Nolte MT, Pirofsky B, Gerritz GA, et al. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979;36:237-43.
11. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1(8541):1075-7.
12. Melamed I, Stein MR, Wasserman RL, Leibl H, Engl W, Yocum RC, et al. Recombinant human hyaluronidase facilitates dispersion of subcutaneously administered Gammagard liquid and enables administration of a full monthly dose in single site to patients with immunodeficiency diseases. J Allergy Clin Immunol. 2008;121(2):S83. Abstract #321.
13. Schiff RI, Wasserman RL, Melamed I, Stein M, McCoy B, Leibl H, et al. Tolerability of immunoglobulin subcutaneous 10% administered SC following administration of recombinant human hyaluronidase in subjects with PID. XIVth Meeting of the European Society for Immunodeficiencies. Istanbul, Turkey, Oct. 6-10, 2010.
14. Data on File. Westlake Village, CA: Baxter Healthcare Corporation; 2012.
15. Daly PB, Evans JH, Kobayashi RH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy. 1991;67(5):504-10.
16. Gardulf A, Bjorvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993;92:200-4.
17. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365-9.
18. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105-16.
19. Kittner JM, Grimbacher B, Wulff W, et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26:400-5.
20. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65-72.
21. Berger M, Murphy E, Riley P, et al. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856-63.
22. Kaveri SV, Maddur MS, Hegde P, et al. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164 Suppl 2:2-5.
23. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354-60.
24. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21-30.
25. Bonagura VR, Marchlewski R, Cox A, et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210-2.
26. Misbah S, Kuijpers T, van der Heijden J, et al. Bringing immunoglobulin knowledge up to date: how should we treat today? Clin Exp Immunol. 2011;166(1):16-25.
27. Food and Drug Administration. Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm078526.pdf. June 2008. Accessed 12/1/2011.
28. Gammagard Liquid [immune globulin intravenous (human)] 10% Prescribing Information. Westlake Village, CA: Baxter Healthcare Corporation, July, 2011.
29. Gamunex-C (Immune Globulin Intravenous [Human] 10% Caprylate/ Chromatography Purified) 10% Liquid Preparation Prescribing Information. Research Triangle Park, NC: Talecris Biotherapeutics, Inc., 2010.
30. Hizentra Immune Globulin Subcutaneous (Human) 20 % Liquid Prescribing Information. Kankakee, IL: CSL Behring LLC, 2010.
31. Vivaglobin Immune Globulin Subcutaneous (Human) 16 % Liquid Prescribing Information. Kankakee, IL: CSL Behring LLC, 2010
32. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol. 2006;6:523-7.
33. Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med. 2010;122(5):176-84.
34. Food and Drug Administration: Title 21-Food and Drugs, Chapter I - Food and Drug Administration, Department of Health and Human Services, Subchapter F-biologics, part 640 additional standards for human blood and blood products. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart= 640&showFR=1&subpartNode=21:7.0.1.1.7.10. Revised April 1, 2011. Accessed 12/1/2011.
35. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf. 2007;2:9-18.
36. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. 2008;28(4):765-78. viii.
37. Jolles S, Sewell WAC, Mishah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1-11.
38. Immune Deficiency Foundation. Characteristics of Immune Globulin Products Currently Licensed for Use in the United States. Updated 2011. http://primaryimmune.org/wp-content/uploads/2011/11/Ig-Therapy-Chart-rv-10.11. pdf. Accessed 12/7/2011.
39. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005;62 Suppl 3:S5-11.
40. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol. 2012;129(3):628-34.
41. Siegel J. Immune Globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. 2011; Jan:23-29.
42. Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PID. J Clin Immunol. 2011;31(5):924-6.
43. Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep. 1999;48(24):518-21.
44. Gaines AR, Pierce LR, Bernhardt PA. Hyperglycemia: falsely elevated blood glucose readings with a point-of-care meter due to a maltose-containing intravenous immune globulin product. 6/18/2009. http://www.fda.gov/ BiologicsBloodVaccines/SafetyAvailability/ucm155099.htm. Accessed 5/18/2011.
45. Food and Drug Administration. Urgent-Voluntary Market withdrawal of Octagam [Immune globulin Intravenous (human)] 5 % liquid preparation. August 20, 2010. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ ucm223897.htm. Accessed 3/8/2012.
46. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients.Pharmacother. 2002;22(12).
47. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6:257-9.
48. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247-51.
49. Shah S, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm. 2005;62(7):720-5.
50. Sati HI, Ahya R, Watson HG. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol. 2001;113(2):556-7.
51. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol. 2006;1(4):844-52.
52. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532-8.
53. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48-51.
54. Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158 Suppl 1:14-22.
55. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158 Suppl 1:51-9.
56. European Society for Immunodeficiencies. Additional Statistics. http://www.esid.org/registry-additional-statistics. Accessed 6/4/2012.
57. Thépot S, Malphettes M, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol. 2010;30(4):602-6.
58. EMA. Note for guidance on the investigation of normal human immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/283/00. 2002. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 10/WC500004255.pdf. Accessed 6/1/2012.
59. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan S, Jolles RL, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012. doi: 10.1111/j.1365-2249.2012.04594.x.
60. Berger M. Subcutaneous Administration of IgG. Immunol Allergy Clin N Am. 2008;28:779-802.
61. Gardulf A, Bjorvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: The patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs. 1995;21:917-27.
62. Roifman CM, Schroeder H, Berger M. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003;3(9):1325-33.
63. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30(2):301-7.
64. Food and Drug Administration. Summary Basis for approval Vivaglobin. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm070585.pdf. Accessed 6/1/2012.
65. Long S, Prober CG, Pickering LK. Principles and Practice of Pediatric Infectious Diseases; 4th ed. 2012. Philadelphia, PA: Churchill Livingstone: An Imprint of Elsevier. ISBN-10: 0443066876.
66. Bonilla F. IgG replacement therapy, no size fits all. Clin Immunol. 2011;139:107-9.
67. Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-31.
68. Wasserman RL, Melamed I, Nelson RP, Knutsen AP, Fasano MB, Stein MR, et al. Pharmacokinetics of Subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-14.
69. Wasserman RL. Common infusion-related reactions to subcutaneous immunoglobulin therapy: managing patient expectations. Patient Prefer Adher. 2008;2:163-6.
70. Berger M, Rojavin M, Kiessling P, et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133-41.
71. von Behring E. The founder of serum therapy. Nobel Prize lecture 1901. http://www.nobelprize.org/nobel-prizes/medicine/laureates/1901/behring-article. html. Accessed 10/25/2011.
72. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencs gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936-42.
73. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-40.
74. Duran-Reynals F. The effect of extracts of certain organs from normal and immunized animals on the infecting power of vaccine virus. J Exp Med. 1929;50(3):327-40.
75. Burket LC, Gyorgy P. Clinical observations on the use of hyaluronidase. Pediatrics. 1949;3(1):56-63.
76. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001;20(8):499-508.
77. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114:230-41.
78. Bywaters EGL, Holborow EJ, Keech MK. Reconstitution of the dermal barrier to dye spread after hyaluronidase injection. Br Med J. 1951;2:1178-83.
79. Knight E, Carne E, Novak B, El-Shanawany T, Williams P, Pickersgill T, et al. Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. J Clin Pathol. 2010;63:846-7.
80. Wasserman RL, Melamed I, Sein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodefieicncy. J Allergy Clin Immunol; 2012 (In Press).
81. Melamed I, Wasserman R, Stein M, Rubenstein A, Puck J, Gupta S, et al. Long-term safety and pharmacokinetics of facilitated subcutaneous infusion of immune globulin (human) 10% and recombinant human hyaluronidase (IgHy) in a phase 111 extension study in patients with primary immunodeficiency (PI). Clinical Immunology Society Annual Meeting. 2012.
82. Stein M, Wasserman RL, Melamed I, et al. Tolerability and efficacy of recombinant human hyaluronidase (rHUPH20)-facilitated subcutaneous infusion of immune globulin (human), 10% (IGHy) in patients with primary immunodeficiency disease (PI). American College of Allergy, Asthma & Immunology, Boston, MA Nov 3-8, 2011, Poster #268.
83. Wasserman RL, Melamed I, Stein, et al. Pharmacokinetics of recombinant human hyaluronidase (rHUPH20)-facilitated subcutaneous infusion of immune globulin (human), 10 % (IGHy) in patients with primary immunodeficiency disease (PI). American College of Allergy, Asthma & Immunology, Boston, MA Nov 3-8, 2011b, Poster #267.